Healome Therapeutics raised £2.0M in an initial financing round led by Empirical Ventures to advance its technology for ophthalmic drop-matrix delivery aimed at treating ocular surface diseases. The funding is likely supportive for early-stage R&D progress, but it is not expected to materially move broader public-market prices.
Healome Therapeutics raised £2.0M in an initial financing round led by Empirical Ventures to advance its technology for ophthalmic drop-matrix delivery aimed at treating ocular surface diseases. The funding is likely supportive for early-stage R&D progress, but it is not expected to materially move broader public-market prices.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
